• Revenue growth in the second quarter offsets weaker first quarter
• Growth in Asia well into double digits at 23.4 %
• Earnings with double-digit growth rates

Jena, May 10, 2012 — After six months of the current financial year, Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508) has recorded very good development of its operating business. The instrument manufacturer for analytical measuring technology and life science generated consolidated revenue of EUR 46.0 m (previous year: EUR 44.5 m). With growth rates of 26.3 % in operating profit (EBIT), 156.2 % in earnings before tax, 156.3 % in consolidated net profit for the period and 161.5 % in earnings per share, the company considerably improved its earnings situation after six months compared with the previous year.

“We succeeded in compensating for the somewhat weaker start to the new financial year and have achieved significant progress year-on-year on the revenue and income side. We have thus created a good base from which we can realize our goals for the financial year as a whole,” said Klaus Berka, CEO of Analytik Jena AG.

Revenue Development and Segments

After the first quarter of the current financial year remained below the previous year, operational business benefited from very good business in the second quarter. As a result, Analytik Jena was able to achieve growth totaling 3.5 % after six months.

Revenue in the Asia region, by far the most important region for the Company, rose considerably once again. In this region, a double-digit gain of 23.4 % was generated after six months, with revenue of EUR 17.5 m (previous year: EUR 14.2 m). For the first time, business in Asia benefited particularly from the development in Japan. In the course of the second quarter, Analytik Jena’s business development accelerated markedly in this market, following the portfolio expansion with x-ray fluorescence devices as part of a distribution partnership with the Japanese company Techno-X.

After the first six months of the current financial year, Analytik Jena also draws an overall positive conclusion in respect to revenue of the three segments. Revenue in the core business Analytical Instrumentation was 6.3 % higher year-on-year at EUR 29.5 m (previous year: EUR 27.7 m). The Life Science business unit achieved revenue of EUR 13.9 m (previous year: EUR 14.3 m) and was down on the previous year’s figures by 2.9 %. This is mainly due to slightly declining revenue at CyBio AG, which is consolidated in this unit. In the smallest business unit, Optics, Analytik Jena generated revenue of EUR 2.6 m (previous year: EUR 2.4 m) in the reporting period, exceeding the previous-year figure by 9.4 %.

Result

Analytik Jena increased its results significantly in the reporting period. The Group generated earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 5.3 m (previous year: EUR 4.5 m), up 18.7 % on the previous year. Operating profit (EBIT) also was up by 26.3 % and amounted to EUR 3.3 m (previous year: EUR 2.6 m) with an EBIT margin of 7.2 % (previous year: 5.9 %). Earnings before tax (EBT) of EUR 2.9 m (previous year: EUR 1.1 m), which more than doubled year-on-year, benefited especially from a positive result from the investment of the 49 % minority interest investment AJZ Engineering and from favorable foreign exchange rate movements in the financial year so far. Overall, the Group posted net profit for the period of EUR 2.0 m (previous year: EUR 0.8 m), which corresponds to an increase of 156.3 %. The share of this attributable to the shareholders of Analytik Jena AG totals EUR 1.8 m (previous year: EUR 0.7 m), which corresponds to earnings per share of EUR 0.34 (previous year: EUR 0.13).

Changes in Statement of Financial Position

The Group’s total assets as of the balance sheet date on March 31, 2012 increased from EUR 83.6 m to EUR 89.1 m. In the reporting period, Analytik Jena showed equity of EUR 45.3 m (as of September 30, 2011: EUR 38.6 m). This corresponds to an increase of 17.5 %, which, in addition to the results contribution, mainly results from the capital increase carried out at the beginning of 2012. The equity ratio rose from 46.1 % as of September 30, 2011 to 50.8 % as of March 31, 2012. On the assets side, cash and cash equivalents increased in the same context by 73.3 % in comparison with the end of the 2010/2011 financial year and amounted to EUR 9.5 m as of the balance sheet date (as of September 30, 2011: EUR 5.5 m). The capital increase of EUR 4.9 m carried out at the beginning of February, which together with external financing was intended in particular for retroactive tax payments, the offer to CyBio AG shareholders in connection with the planned delisting and a strategic expansion of the portfolio, the realization of which failed in retrospect directly before the contract was signed, stabilized the Company’s liquidity position and improved the equity base. In the reporting period, Analytik Jena recorded operating cashflow of EUR 1.5 m.

Human Resources

As of the balance sheet date of March 31, 2012, the Group employed 813 staff, including 37 trainees (previous year: 800 employees, including 39 trainees).

Outlook

Based on the good first half of 2011/2012, Analytik Jena expects the positive development of its business to continue over the year as a whole. The Company anticipates that all three segments will contribute to revenue and earnings growth. In line with its forecast for the year, Analytik Jena AG estimates the expected consolidated revenue for the financial year 2011/2012 at between EUR 91.0 m and EUR 93.0 m as well as expected operating profit at more than EUR 6.0 m.

Further Information

The full financial report is available at http://berichte.analytik-jena.de/6-MonthReport_1112.pdf.

Jena, May 7, 2012 – On May 3 and 4, 2012, Analytik Jena AG held its 2012 "Life Science Conference". For the second time, the Company sponsored this event for exchanging news and views, offering clients and scientists from the German-speaking region in particular the chance to learn about current scientific research topics and analytical trends from the world of biotechnology and molecular diagnostics. This year, the Company welcomed nearly 150 attendees to its group headquarters in Jena; demand for this relatively new event series has thus grown appreciably.

In his welcome speech to the attendees, Klaus Berka, CEO of Analytik Jena AG, noted: "It is true that we have just begun our ventures in life sciences, which is growing rapidly around the world. But we are making good progress as a renowned systems provider, and the incredible amount of interest in this event proves that we are on the right track."

Thanks to the success of the 2010 "Life Science Conference", this event quickly gained a reputation as a platform for discussions on life science topics and innovative research issues. The response after two conference days was also very positive.

Dr. Ulrich Busch from the Bavarian State Agency for Health and Food Safety (LGL), one of the conference speakers, explained: "This event was very successful and interesting. It included everything from practical research topics to the future of Analytik Jena."
As Angela Hilbert from the Friedrich Löffler Institute in Wusterhausen noted, "It was a positive event for me. The innovative and forward-looking technologies really impressed me, and will be of great interest to me in my further work."
Dr. Antje Labes, GEOMAR noted: "An all-around great event! The seminar was very in-depth and offered a mix of very interesting participants. I feel this is a unique conference for the German-speaking region. And since I am a user myself, I really enjoyed visiting Analytik Jena's headquarters."

Press fotos are available for download at http://www.analytik-jena.de/en/Investor-Media-Relations/Press-Center/Downloads__3885/ zum Download zur Verfügung.

For more information on the 2012 Life Science Conference, see www.analytik-jena.de/de/site__4882.

Jena/Dubai, May 3, 2012 — Analytik Jena AG has strengthened its sales and service presence in the Middle East region and opened an office in Dubai. From there, the Company will manage its entire sales activities in the Middle East region. The new facilities in the Silicon Oasis technology park also house a seminar and training room as well as an applications laboratory. The formal opening now took place with more than 50 guests from 25 countries and representatives of Analytik Jena on the occasion of the regional annual retailers’ meeting.

"We are doing all we can to expand our international network — which combines our expertise and services for our customers — on an ongoing basis. In opening the Dubai office, we want to expand our position in the markets in the Middle East further," says Klaus Berka, CEO of Analytik Jena AG. "At the Dubai site, from this point onwards the varied range of services of the Analytical Instrumentation and Life Science divisions are combined for the entire region."

With the new office, Analytik Jena is also reacting to the growing need for consultation, seminar and training opportunities in the region. From the Competence Center in Dubai, this need can now be covered with shorter reaction times. Product demonstrations and user training, supervised by experienced application specialists, can take place in the demonstration laboratory using the devices directly. Furthermore, Analytik Jena is cooperating closely with the partner company Gulf Analytical Instruments International to achieve comprehensive customer service in the United Arab Emirates.

Jena, April 24, 2012 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) expects another sales and earnings increase for the current financial year 2011/2012. The Company forecasts consolidated sales of approximately EUR 91.0 m to EUR 93.0 m. Analytik Jena wants to achieve more than EUR 6.0 m in operating profit (EBIT) at the end of the period. In the 2010/2011 financial year, the Company generated consolidated sales of EUR 86.3 m as well as EBIT of EUR 5.0 m.

“Overall, we are satisfied with business in the first half of the year. We managed to make up for the weaker performance of the first quarter and have clearly exceeded the previous year’s level already half-way through the year. Improving business in Japan contributed particularly to this. We anticipate a continuation of this in the second half of the year,” said Klaus Berka, CEO of Analytik Jena AG.

Analytik Jena expects all three segments to contribute to the growth in sales and earnings. In particular, Life Science and Optics, the two divisions still in a weaker position, must make clear gains in the second half of the year in order to achieve this objective. In Life Science, the Company anticipates that the efforts in international sales development, particularly in China and the Arab countries, will pay off with the new regional office in Dubai. In Optics, the Company can point to a high order volume in the core business and in OEM products.

In the most important division, Analytical Instrumentation, Analytik Jena anticipates a continuation of the current very positive development. The Company expects a clear sales increase in the Japanese market – especially with the new product line of X-ray fluorescence equipment.

The Company is set to announce the complete figures for the second quarter and for the first six months of 2011/2012 on May 10, 2012.

Jena, April 20, 2012 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) has acquired the remaining shares in its subsidiary AJ Roboscreen GmbH and is now its sole owner with 100.0%. The Jena-based manufacturer of analytical instrumentation technology, life science instruments and optoelectronics has thus integrated another subsidiary further into the Group.

"We are pursuing a very clear strategic path and wish to expand our expertise in the Life Science division further. The acquisition of the remaining approximately 50% of the shares in AJ Roboscreen allows us to meet the requirement of combining our expertise in molecular diagnostics and protein analytics with the expertise in the Group," said Klaus Berka, CEO of Analytik Jena AG.

In the future, in the Life Science growth segment, Analytik Jena wants to direct its focus more on the business with reagents, whereby the closer integration of the Leipzig-based subsidiary AJ Roboscreen GmbH is to play a central role. AJ Roboscreen GmbH develops diagnostic kits, reagents, fine chemicals and disposable consumables for the standardized purification and detection of nucleic acids as well as for detecting specific proteins. Admittedly, the diagnostics of neurodegenerative diseases, such as Parkinson’s or Alzheimer’s, still encompass a comparatively small market. However, in the long term, they harbor enormous potential.

Jena/Munich, April 16, 2012 — At this year’s analytica, which takes place from April 17 to 20, 2012 in Munich, Analytik Jena AG (Hall A1, Stand 211/310) is set to showcase technology trends of the future with its broad portfolio in the fields of analytical instrumentation technology, life science and LIMS.

One trade fair highlight in the field of traditional analytical instrumentation technology is the contrAA^® series, a device family for high-resolution continuum source atomic absorption spectrometry (HR-CS AAS) that is unique on the market. The contrAA® devices allow for the first time ever simultaneous multi-line detection as well as the detection of non-metals such as halogens or sulfur. Alongside the compact contrAA^® 700 combination device, the latest addition to the product family − the contrAA^® 600 for graphite furnace, HydrEA and direct solids analysis − will also be on show. Potential customers can not only admire the new contrAA^® 600 on the Analytik Jena stand, but also see it in action in the live laboratory for food and water analysis in Hall B2 − a brand-new highlight of the analytica 2012 trade fair.

The multi N/C^® series also offers some new innovations: These TOC/TN_b analyzers now feature innovative thermo-catalytic decomposition technology that allows for a much higher sample throughput, a much longer service life and drastically reduced operating costs in all applications, particularly for extreme matrices and samples with a high salt content. Analytik Jena will also be presenting the multi EA^® 5000, a new generation of elemental analyzers for the single-and multi-element analysis of carbon, nitrogen, sulfur and chlorine from solid, pasty, liquid and gaseous samples. The process of detecting sulfur quickly and without interference has been further optimized thanks to the newly developed Micro Plasma Optimizer technology. The multi X^® 2500 AOX analyzer and the latest UV/VIS spectrophotometers in the SPECORD^® PLUS series round off the business unit’s product range at the trade fair.

In the Life Science area, Analytik Jena will showcase two new real-time PCR systems: the qTOWER for quantitative real-time rapidPCR and the TOptical for real-time PCR. The new CyBi^®-FeliX, an extremely compact bench-top pipettor for use in proteomics and genetics developed by subsidiary CyBio AG, will also be showcased. Based on the patented CHOICE technology, this flexible pipetting platform allows for a volumetric area four times bigger than was previously possible. The wide range of pipetting formats allows flexible, single-channel, row-by-row, column-by-column and parallel 96/384 handling. In combination with 12 deck positions, CyBi^®-FeliX is the perfect solution for a range of automated, routine liquid handling tasks.

AJ Blomesystem GmbH will be presenting the newly launched readyLIMS^®, a high-performance, turnkey laboratory information management system designed for the complete range of laboratory-based tasks. This subsidiary of Analytik Jena will also be showcasing its tried-and-tested LIMS solutions LABbase^® and ENMO^® hydro.

For more information, visit http://www.analytik-jena.de/en/analytica__4853/.

Press Event:
Press conference with tour of the Analytik Jena stand and subsequent Thuringian Evening
When: Thursday, April 19, 2012, at 4:30 p.m.
Where: Hall A1, stand 211/310